<DOC>
	<DOCNO>NCT01478399</DOCNO>
	<brief_summary>Primary objective : To compare pharmacokinetic profile Glymera ( PB1023 ) Injection single dose administer subcutaneous injection subject normal renal function impair renal function . Secondary objective : To evaluate safety tolerability Glymera ( PB1023 ) Injection administer subcutaneous injection adult subject normal renal function impair renal function .</brief_summary>
	<brief_title>Pharmacokinetic , Safety/Tolerability Study Single SC Dose PB1023 Injection Subjects With Normal Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Males female age 18 79 year age inclusive . BMI 19 40 kg/m2 . Renally Impaired Subjects : In otherwise stable health except Renal Disease . Healthy volunteer must have/be : eGFR calculate MDRD ≥ 80 mL/min , Matched renally impair subject age ( ± 15 year ) , weight ( ± 15 kg ) , possible BMI , race gender . Subjects renal impairment must 2 separate eGFR within 20 % clinically stable minimum 6 month . No clinically relevant abnormality result laboratory screening admission evaluation consistent renal impairment relate disease/disorder appropriate subject group determine Investigator . Currently take take GLP 1 agent ( e.g. , Byetta® , Victoza® ) within past year . Subjects previously receive PB1023 . Known allergy serious adverse effect approve investigational GLP1 receptor analog/agonist . Serious Infection within 60 day admission . Donation loss great 400 mL blood 56 day prior enrollment . Unstable cardiovascular disease define per protocol . Clinically significant hepatic dysfunction define per protocol . Female subject pregnant , try become pregnant lactating . Known history active alcohol drug abuse within 12 month prior Screening positive alcohol and/or drug screen . Positive Human Immunodeficiency Virus ( HIV ) antibody , Hepatitis B surface antigen ( HBsAg ) Hepatitis C Virus ( HCV ) antibody . Participating study time screen observational study receive investigational drug device within 30 day 5 halflives prior dose take part nondrug study opinion Investigator would interfere outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>